Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

IntroductionEculizumab is a C5 complement inhibitor approved by the FDA for the targeted treatment of four rare diseases, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and aquaporin-4 immunoglobulin G-positive optic neuromy...

Full description

Saved in:
Bibliographic Details
Main Authors: Xi-Feng Wang, Lu-Ri Bao, Ta-La Hu, Rui-Feng Xu, Wu-Niri Gao, Jing-Yuan Wang, Jian-Rong Zhao, Zhen-Li Fu, Shu-Fang Wang, Yan Meng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pharmacology
Subjects:
eculizumab
FAERS
adverse drug events
adverse drug reaction monitoring
ADRM
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1440907/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items